基本信息
浏览量:2
职业迁徙
个人简介
Hypoxia, a consequence of tumor cells outgrowing their blood supply, and subsequent angiogenesis are two of the hallmarks of rapidly growing solid tumors. Dr. Zhou's laboratory has been exploiting these unique pathological features for developing novel therapeutic approaches.
The hypoxic tumor compartment poses challenges for both chemo and radiation therapies as hypoxia diminishes the therapeutic effects of chemotherapeutic agents and radiation. Conversely, this tumor compartment, hypoxic and immune-privileged, provides a unique niche for anaerobic bacteria to grow. C. novyi-NT is an attenuated strain of the anaerobic bacterium Clostridium novyi. When injected intravenously, C. novyi-NT spores are not toxic to healthy animals but can selectively germinate within and colonize tumors, resulting in massive necrosis and tumor regression. In addition to direct tumor destruction by bacterial growth, the C. novyi-NT infection elicits a potent host antitumor immune response leading to long-term cures. C. novyi-NT is considered a promising anticancer agent not only for its inherent anticancer properties, but also for its capacity to enhance other cancer therapies and to serve as a tumor-specific gene therapy vector. Dr. Zhou's laboratory has combined C. novyi-NT spores with chemotherapeutic drugs, liposomal formulation of chemotherapeutic drugs, and radiation for the treatment of several experimental tumor models. The combination therapies showed marked improvement in efficacy over the therapies using individual agents. Dr. Zhou's group is currently generating engineered C. novyi-NT strains that are more potent and less toxic in several experimental tumor models.
In response to the increased demands for nutrients and oxygen, solid tumors establish their own vascular networks that are both structurally and physiologically different from the vasculature in normal tissues. These differences form the basis for a therapeutic approach Dr. Zhou's laboratory has been developing. Both biologic and chemical agents capable of inducing vascular responses akin to those observed in inflammatory processes enhance the selective accumulation of nanoparticles in tumors. For example, the proinflammatory cytokine TNF-alpha is able to increase the tumor to blood ratio of sterically stabilized liposomes by more than 20-fold compared to the liposomes alone. Consequently, the vascular-active agents dramatically improve the therapeutic effect of liposomes containing radioactive isotopes or chemotherapeutic agents. Dr. Zhou's group is investigating a variety of vascular-active agents for their ability to augment selective tumor accumulation of nanoparticles.
The hypoxic tumor compartment poses challenges for both chemo and radiation therapies as hypoxia diminishes the therapeutic effects of chemotherapeutic agents and radiation. Conversely, this tumor compartment, hypoxic and immune-privileged, provides a unique niche for anaerobic bacteria to grow. C. novyi-NT is an attenuated strain of the anaerobic bacterium Clostridium novyi. When injected intravenously, C. novyi-NT spores are not toxic to healthy animals but can selectively germinate within and colonize tumors, resulting in massive necrosis and tumor regression. In addition to direct tumor destruction by bacterial growth, the C. novyi-NT infection elicits a potent host antitumor immune response leading to long-term cures. C. novyi-NT is considered a promising anticancer agent not only for its inherent anticancer properties, but also for its capacity to enhance other cancer therapies and to serve as a tumor-specific gene therapy vector. Dr. Zhou's laboratory has combined C. novyi-NT spores with chemotherapeutic drugs, liposomal formulation of chemotherapeutic drugs, and radiation for the treatment of several experimental tumor models. The combination therapies showed marked improvement in efficacy over the therapies using individual agents. Dr. Zhou's group is currently generating engineered C. novyi-NT strains that are more potent and less toxic in several experimental tumor models.
In response to the increased demands for nutrients and oxygen, solid tumors establish their own vascular networks that are both structurally and physiologically different from the vasculature in normal tissues. These differences form the basis for a therapeutic approach Dr. Zhou's laboratory has been developing. Both biologic and chemical agents capable of inducing vascular responses akin to those observed in inflammatory processes enhance the selective accumulation of nanoparticles in tumors. For example, the proinflammatory cytokine TNF-alpha is able to increase the tumor to blood ratio of sterically stabilized liposomes by more than 20-fold compared to the liposomes alone. Consequently, the vascular-active agents dramatically improve the therapeutic effect of liposomes containing radioactive isotopes or chemotherapeutic agents. Dr. Zhou's group is investigating a variety of vascular-active agents for their ability to augment selective tumor accumulation of nanoparticles.
研究兴趣
论文共 117 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Bum Seok Lee,Ashley Cook, Maged Zeineldin,Surojit Sur, Laura Dobbyn,Maria Popoli, Sana Khalili,Bert Vogelstein,Nickolas Papadopoulos,Shibin Zhou,Chetan Bettegowda,Phillip Buckhaults,
Cancer Researchno. 6_Supplement (2024): 6844-6844
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Ashley L. Cook, ojit Sur, Laura Dobbyn,Evangeline Watson,Joshua D. Cohen, Blair Ptak, Bum Seok Lee,Suman Paul, Emily Hsiue,Maria Popoli,Bert Vogelstein,Nickolas Papadopoulos,
Cancer Researchno. 6_Supplement (2024): 2082-2082
Tushar D. Nichakawade, Jiaxin Ge,Brian J. Mog, Bum Seok Lee, Alexander H. Pearlman,Michael S. Hwang,Sarah R. DiNapoli,Nicolas Wyhs, Nikita Marcou,Stephanie Glavaris,Maximilian F. Konig,Sandra B. Gabelli,
Naturepp.1-8, (2024)
Brian J. Mog,Sarah R. DiNapoli,Michael S. Hwang, Tushar D. Nichakawade,Jacqueline Douglass,Emily Han‐Chung Hsiue,Katharine M. Wright,Alexander H. Pearlman,Maximilian F. Konig,Suman Paul,Nicolas Wyhs, Nikita Marcou,
Cancer Researchno. 8_Supplement (2023): LB095-LB095
引用0浏览0引用
0
0
引用1浏览0WOSNATURE引用
1
0
Ashley L Cook,Surojit Sur, Laura Dobbyn,Evangeline Watson,Joshua D Cohen, Blair Ptak, Bum Seok Lee,Suman Paul, Emily Hsiue,Maria Popoli,Bert Vogelstein,Nickolas Papadopoulos,
bioRxiv : the preprint server for biology (2023)
bioRxiv : the preprint server for biology (2023)
引用0浏览0WOS引用
0
0
Brian J. Mog,Sarah R. DiNapoli,Michael S. Hwang, Tushar D. Nichakawade,Jacqueline Douglass,Emily Han-Chung Hsiue,Katharine M. Wright, Alexander H. Pearlman,Maximilian F. Konig,Suman Paul,Nicolas Wyhs, Nikita Marcou,
CANCER RESEARCHno. 8 (2023)
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn